A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants
Status:
Recruiting
Trial end date:
2021-10-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the relative bioavailability and food effect of a
single dose of milvexian administered as direct compression (DC) oral tablets and roller
compacted (RC) oral tablets compared with milvexian administered as Phase 2 oral capsules
(Part 1) and of new concept tablets consisting of a single dose of milvexian administered as
oral Tablet 1 and Tablet 2 compared with milvexian administered as Phase 2 oral capsules
(Part 3) in healthy participants under fasting and fed conditions; to characterize the
pharmacokinetics (PK) of multiple twice daily (BID) doses for 5 days of milvexian
administered as DC oral tablets and Phase 2 oral capsules in healthy participants (Part 2)
and to assess the effects of dosing time and food timing on the PK of single-dose of
milvexian Phase 3 oral tablet formulation in healthy participants (Part 4).